Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss for the period | -7,053 | -8,175 | -7,976 | -26,419 |
| Depreciation of property and equipment (note 5) | 93 | 62 | 93 | 218 |
| Amortization of intangible assets (note 6) | 7 | 47 | 54 | 86 |
| Non-cash lease expense adjustment | -50 | 9 | 9 | 19 |
| Share-based compensation (note 11) | 1,048 | 1,381 | 1,669 | 2,440 |
| Interest and accretion expense | 5 | 5 | 7 | 51 |
| Trade and other receivables (note 3) | 2,240 | -736 | 3,357 | -2,449 |
| Inventory (note 4) | 996 | 229 | -130 | 2,723 |
| Prepaid expenses and deposits | -105 | 694 | -116 | -1,042 |
| Accounts payable, accrued expenses and other liabilities (note 7) | 311 | 40 | -207 | 545 |
| Deferred revenue | 88 | 270 | -216 | 317 |
| Income taxes payable | -56 | - | 58 | - |
| Income taxes payable (note 13) | - | 42 | - | - |
| Deferred tax liabilities | - | - | 24 | -14 |
| Deferred tax asset | 3 | -26 | - | - |
| Net cash used in operating activities | -8,583 | -6,566 | -9,614 | -22,027 |
| Purchase of property and equipment (note 5) | - | 176 | - | - |
| Purchase of intangible assets (note 6) | - | 66 | - | - |
| Net cash used in investing activities | - | -242 | - | - |
| Issuance of commons shares (note 10) | - | 42,436 | - | - |
| Payments of financing costs (note 10) | - | 1,016 | - | - |
| Repayments of long-term debt (note 8) | - | 0 | 0 | 290 |
| Proceeds from the exercise of stock options (note 11) | - | 8 | - | - |
| Net cash provided by financing activities | - | 41,428 | 0 | -290 |
| Net increase (decrease) in cash | -8,583 | 34,620 | -9,614 | -22,317 |
| Effect of exchange rate changes on cash | -845 | 277 | 1,845 | - |
| Cash, beginning of period | 59,723 | 24,826 | 54,912 | - |
| Cash, end of period | 50,295 | 59,723 | 24,826 | - |